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INTRODUCTION
The Medical Research Council (MRC)- National Institute 
for Health Research (NIHR) Review of Nutrition and 
Human Health Research 2017 report highlighted the 
need to ‘pull- through’ a strong basic science nutrition 
portfolio in the UK into a population health and eco-
nomic benefit (MRC, 2017). The UK Nutrition Research 
Partnership awards, funded by the MRC in partner-
ship with the Biotechnology and Biological Sciences 
Research Council and NIHR, were established to take 
forward this agenda, including supporting ‘Hot Topic’ 
workshops that would provide novel and robust insights 
into human nutrition and enhance interdisciplinary 
collaborations.
The overall objective for this workshop was to prog-
ress ideas and planning for a potential UK- wide nutrition 
primary prevention randomised controlled trial (RCT) 
with incident disease as the study endpoint: the UK 
Nutrition and Healthy Life Expectancy (NuLifE) Trial.
This workshop was organised by the principal in-
vestigator Anne- Marie Minihane (AMM), along with 
an early career researcher, co- principal investigator, 
Jennifer Carter (JC). A working group of key collabo-
rators that helped with the planning of the workshop 
were John Mathers (JM), Susan Jebb (SJ), Susan 
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Abstract
There is a drive in the UK to harness findings from novel fundamental and ef-
ficacy nutritional research and, through inter- disciplinary and multi- agency col-
laborations, to improve eating behaviour for the benefit of population health. This 
report summarises the progress made during the Medical Research Council- 
funded Hot Topic workshop on the planning for a potential UK- wide nutrition 
primary prevention randomised controlled trial with incident disease as the study 
endpoint: the UK Nutrition and Healthy Life Expectancy (NuLifE) Trial. Through 
two workshops, along with online discussions and a systematic evidence syn-
thesis, over 40 experts from a range of disciplines came together over 6 months. 
The workshop reached a consensus and delivered a three- stage plan with the 
ultimate ambitious aim of providing effective eating behaviour change strate-
gies to address the growing inequalities in the UK and contribute to both a re-
duced risk of prevalent diet- related chronic disease and an increase in healthy 
life expectancy.
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Fairweather- Tait (SF) and Naveed Sattar (NS), with 
Amy Jennings (AJ) conducting a systematic review to 
inform the NuLifE trial design. The workshops were 
attended by 42 participants from 19 organisations 
with expertise in nutritional epidemiology, nutritional 
science, behavioural science, ageing, public health, 
chronic disease pathology, weight loss, nutrige-
nomics, health inequalities, clinical trial design and 
delivery, business strategy, public policy, health eco-
nomics and digital technology (Appendix A). Senior 
researchers were encouraged to identify early career 
researchers to attend.
RATIONALE FOR THE WORKSHOP
Although beginning to plateau, life expectancy (LE) in 
the UK has increased 2– 3 years every decade for the 
last century and currently stands at 79 and 83 years for 
males and females. However, healthy life expectancy 
(HALE) is not increasing at the same rate, with an in-
creased rate for HALE:LE of 0.8 (ONS, 2018). This is 
in effect creating one additional year of ill health per 
person every 15 years. Furthermore, there are large in-
equalities evident, with 18 years difference in HALE ev-
ident in England between the lowest and highest Index 
of Multiple Deprivation (IMD) groups (ONS, 2018). This 
trajectory is unsustainable for NHS and social care de-
livery. The UK Government's ‘Ageing Society’ Grand 
Challenge set a mission to increase HALE by 5 years 
(from 63 to 68 years) by 2035, with the planned NuLifE 
programme in direct response to this ambitious target 
(BEIS, 2019).
Suboptimal diet is the number one modifiable deter-
minant of HALE and chronic disease risk globally, and, 
in the UK, is responsible for 15– 20% of the population 
attributable fraction of years of life lost (Afshin et al., 
2019; Steel et al., 2018). Current UK dietary recommen-
dations and public health policy are based largely on 
evidence from prospective cohort studies. There is lim-
ited evidence from efficacy trials which typically exam-
ine the short- term impact of select dietary components 
or foods on biochemical, functional and imaging- based 
surrogate markers of disease, as the primary endpoint. 
The actual impact and size effect of a whole diet inter-
vention on incident disease is completely unknown. In 
addition, the approaches necessary to implement such 
an intervention by achieving long- term changes in in-
dividual and community eating behaviour are unidenti-
fied and untested.
The remit for a NuLifE primary prevention trial is 
therefore important and timely. The long- term aim of 
the programme is to establish the impact of a whole- 
diet nutrition intervention on the risk of transition from 
health to a clinical diagnosis of disease in ‘at- risk’ UK 
adults.
AIMS OF THE WORKSHOP
1. Fully consider the need for and impact of the 
NuLifE trial.
2. Develop linkages between disciplines (nutrition, trial-
ists, primary and secondary care, health economics, 
digital health, behavioural science, food industry/re-
tailer, the public) and identify discipline gaps.
3. Advance the research questions and trial design.
4. Develop a plan and timeline for delivering the NuLifE 
programme and funding strategy.
WORKSHOPS STRUCTURE
The workshop was delivered as two half- day virtual 
events, held on the 28th September 2020 and the 17th 
February 2021. Prior to the first meeting, the following 
documents were provided to all registered participants 
to show the relevant policy and scientific background to 
the NuLifE remit.
• A summary of the workshop bid to the MRC
• Infographic of the UK Eatwell Guide (PHE, 2016a)
• Public Health England's dietary recommendations 
for the UK 2016 (PHE, 2016b)
• Mortality and life expectancy trends in the UK 
(Marshall et al., 2019)
• Advancing our Health: Prevention in the 2020s 
(Department of Health & Social Care, 2019)
• World Health Organization: Risk reduction of cogni-
tive decline and dementia 2019 (WHO, 2019)
• Schulze M et al., Food based dietary patterns and 
chronic disease prevention (Schulze et al., 2018)
• Scheelbeek P, Dangour A et al., Health impacts 
and environmental footprints of diets that meet the 
Eatwell Guide recommendations: analyses of multi-
ple UK studies (Scheelbeek et al., 2020)
• Slide sets summarising previous nutrition randomised 
controlled trials (Nu- AGE, CRESSIDA, PREDIMED, 
Food4Me, MedEx) (Berendsen et al., 2018; Celis- 
Morales et al., 2017; Estruch et al., 2018; Reidlinger 
et al., 2015; Shannon et al., 2021)
NULIFE WORKSHOP 1
Key presentations
The first NuLifE workshop began with an overview of 
the workshop justification from AMM. To inform the 
possible disease end- point focus for NuLifE, AMM pre-
sented the UK LE, HALE and morbidity and mortality 
statistics. Dementia is the number one cause of mor-
tality in England and Wales accounting for 12.8% of 
total deaths in 2017, with dementia and cardiovascular 
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diseases collectively responsible for 40% of total deaths 
(ONS, 2017). Two- thirds of the UK population are either 
overweight or obese, with a greater prevalence in those 
who are most deprived (NHS Digital, 2020). Reflecting 
on key UK nutrition and dietary guidelines as opera-
tionalised in the Eatwell Guide, and current population 
diet and nutrition data, large proportions of the popula-
tion are not meeting current dietary targets and there 
is an evident socio- economic gradient (Bates et al., 
2019). In a 2020 analysis using data from 2012 to 2017 
in the National Dietary and Nutrition Survey (NDNS), 
population adherence for nine of the Eatwell Guide rec-
ommendations ranged from 7% to 80%, with the low-
est adherence for fibre, oily fish and sugar (Scheelbeek 
et al., 2020).
To fuel breakout room discussions, and put the 
subsequent key presentations into perspective, AMM 
presented some initial thoughts (and related ques-
tions) around the potential PICO (i.e. population, inter-
vention, control, outcome) elements of the NuLifE trial 
(Richardson et al., 1995). For the ‘Population’ element, 
the trial would likely need to recruit participants with 
an ‘at- risk’ profile in order to achieve the required num-
ber of disease cases during the intervention period 
(but how do we define ‘at- risk’?). For the ‘Intervention’, 
should we adopt a whole- diet approach, rather than 
focus on specific nutrients, dietary derived bioactives 
or select foods/food groups? Should the intervention 
be bespoke and personalised? Should the trial be a 
pragmatic, effectiveness trial? For the ‘Control’ arm, 
should it be usual care? For the ‘Outcome’ element, 
do we focus on incident cardio- metabolic disease, 
should we include dementia, and should our composite 
end- point include other major chronic diseases such as 
diet- sensitive cancers?
Lastly, AMM set out a crude sample size calculation 
to set the expectations of attendees to the likely scope 
of the trial. Using event rates from the large prospective 
UK Biobank study of 0.5 million adults in the UK, with 
a high- risk population over the age of 55 years, a com-
posite outcome of cardiovascular disease and type 2 
diabetes with an event rate of approximately 3% a year 
would give a simple two- arm trial over 5 years a power 
of 90% to detect a 10% relative risk reduction if there 
were approximately 16 000 participants (UK Biobank, 
2007).
The following speakers and breakout room discus-
sions expanded on these key elements of trial design 
and the necessary research infrastructure that would 
be needed for a nutrition trial that was much larger than 
any that had been previously attempted in the UK (with 
only a few examples globally; Estruch et al., 2018).
Jane Armitage from the University of Oxford spoke 
about how new opportunities with digital technolo-
gies and data linkage could enhance the ability to 
run streamlined trials at scale with lower costs and 
improved quality. Giving examples from the large- 
scale ORION- 4 and ASCEND trials (ClinicalTrials.gov 
Identifier: NCT03705234; NCT00135226), she high-
lighted the importance of simple inclusion criteria; and 
the use of electronic health records to identify large 
numbers of participants, screen and consent them effi-
ciently, and follow them up more completely for a wide 
range of events (Mafham et al., 2020).
Falko Sniehotta from the University of Newcastle 
gave a summary of the particular challenges of 
TA B L E  1  Summary of Population, Intervention, Control, Outcome (PICO) elements discussed during breakout rooms in NuLifE 
workshop 1
PICO breakout room Main discussion points
Population • Challenges of working in deprived areas, but possible target for greatest effect
• Using GP surgeries to recruit high- risk patients
• Potential screening for those with low- quality diets at baseline (vs. using streamlined recruitment 
methods)
Intervention/Control • A whole- diet approach (e.g. Eatwell Guide)
• Consideration of sustainability
• Personalised tailoring of intervention elements with web- based tools
• Involvement of retailers
• Consideration of difficulties that takeaway food differs across the country, and general difficulties 
of randomisation in a whole- diet approach
• Control group is usual care for high- risk groups
Outcome • Composite outcome to increase number of events
• Need a clear causal pathway targeted by nutrition over a 5- year period
• Previous nutrition efficacy trials have shown effects on intermediate mechanisms for 
cardiometabolic diseases like cardiovascular disease and diabetes
• Need a different outcome for an interim pilot study, such as blood pressure, that would 
demonstrate efficacy of the intervention quickly
• What to do about weight loss? Is this an outcome to aim for, or would it confuse the picture?
Study design • Effectiveness or efficacy trial?
• Factorial design with personalised tailoring
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(Continues)
TA B L E  2  Evidence synthesis of randomised controlled trials using behaviour change to improve diet in the last 5 years
Author Year Intervention groups Participants Duration Outcomes Behaviour change components Dietary change Results
Cho et al. (Cho et al., 2020) 2020 1. nonuser group (control),
2. app- based diet and exercise self- logging 
group (app only)





6 months Blood pressure, weight, 
waist circumference, 
body fat, HOMA- IR 
and lipids
Personalised feedback (Group 3)
Self- monitoring (Group 2 + 3)
Not reported Personalised feedback not 
more effective than 
self- monitoring
Yubero- Serrano et al. (Delgado- Lista et al., 
2016; Yubero- Serrano et al., 2020)
[CORDIOPREV]
2020 1. Mediterranean Diet
2. Low- fat diet
>20 & <76 years,
established heart disease 
without clinical events in the 
last 6 months
n = 1002
7 years Cardiovascular events Personalised interviews, group education 
sessions and food provision to both 
groups
Differences in adherence to the 14 items of 
the MEDAS after 1 year
Study ongoing
Rijnaats et al. (Rijnaarts et al., 2020) 2020 1. Personalised dietary advice (PDA)





6 weeks Fibre intake Personalised advice (web- based service) Participants in the PDA group were 
more likely to adhere to fibre 
recommendations
– 
Hackshaw- McGeagh et al. (Hackshaw- 
McGeagh et al., 2019)
[PrEVENT]




Males with prostrate cancer
n = 81
6 months Adherence (based as 
90% of time)
Printed instructions (group 1)
Supplements (group 2)
40% adhered to FV
72% adhered to dairy
79% adhered lycopene
– 
Kushida et al. (Kushida et al., 2019) 2019 1. 1975 Japanese diet (JD)




4 weeks Change in gut microbiota Three meals daily pre- prepared food (both 
groups)
Not reported Taxa significantly changed 
after consumption of JD
Piernas- Sanchez et al. (Piernas et al., 
2020; Piernas et al., 2019)
[PC- SHOP]
2019 1. Control
2. Health professional advice (HPA)




3 months Saturated fat intake (SFA) Personalised feedback (Group 3)
Advice session (COM- B behaviour change 
wheel) (Group 2 and 3)
No difference in SFA intake or food 
purchasing between groups
No difference in lipid profiles 
compared to control
Duś- Żuchowska et al. (Duś- Żuchowska 
et al., 2018)
2018 1. Mediterranean Diet





(ADMA) and C- 
reactive protein 
(hs- CRP)
Pre- portioned main meals (covering 35% of 
energy) delivered (both groups)
Not reported No between- group differences 
in ADMA or hs- CRP
Katsagoni et al. (Katsagoni et al., 2018) 2018 1. Control
2. Mediterranean diet (MD)
3. Mediterranean lifestyle (ML)
18– 65
With non- alcoholic fatty liver 
disease
n = 63





MD and ML 7 x 1 h group sessions based 
on goal setting theory
ML – diet + activity and sleep
ML and MD improved MD adherence (FFQ 
and 24- h recall)
Ml – improved ALT and liver 
stiffness
ML and MD – weight loss
Kazemi et al. (Kazemi et al., 2018) 2018 1. Pulse- based diet





Two meals (i.e., lunch and dinner) were 
supplied daily for participants in the 
pulse- based diet group
Differences in fibre and micronutrient 
intakes between groups (24- h recalls)
Pulse- based diet decreased 
total insulin AUC, levels of 
LDL- C, TG, TC/HDL- C ratio, 
diastolic blood pressure, 
and increased HDL- C 
compared to control diet
Krishnan et al. (Krishnan et al., 2018) 2018 1. Typical American Diet (TAD)
2. Dietary Guidelines America diet (DGA)
Overweight to obese women, 
less than 150 min/week 
physical activity
≥1 cardiometabolic risk factor
n = 52
8 weeks Glucose homeostasis 
and fasting lipids
All meals provided 30 ± 35 (10.4% ± 0.1% deviation) instances 
of reported deviance from full dietary 
compliance in the DGA group and 
39 ± 31 (13.9% ± 0.1%) instances of 
reported deviance in the TAD group
No between- group differences 
in primary outcomes
Properzi et al. (Properzi et al., 2018) 2018 1. Mediterranean Diet (MD)
2. Low- fat diet
Non- alcoholic fatty liver disease
n = 51
12 weeks % of hepatic steatosis 
(HS)
Food provision (both groups)
Nuts and olive oil for the MD
Natural muesli and low- fat snack bars for 
the low- fat diet
Personalised dietary advice (both groups)
Dietary change achieved in both groups 
(Diet History)
HS reduced in both groups
Winkvist et al. (Winkvist et al., 2018; Vadell 
et al., 2020)








Disease severity Food provision (both groups) equivalent 
50% of the daily intake during 5 
weekdays
Intakes of fibre, EPA, and DHA were 
considerably higher during the 
intervention period (3- d diet record)
No significant differences 
between groups
Jayawardena et al. (Jayawardena et al., 
2017)
2017 1. Control






Personalised advice Not reported Weight reduction relative to 
control. No change in BP 
or lipids
Koutoukidis et al. (Koutoukidis et al., 2017; 
Koutoukidis et al., 2019) [DEUS]
2017 1. Control




8 weeks Adherence to AHEI 2010 
score
Quality of Life (QoL)
Group sessions 77% adhered to intervention (AHEI results 
not reported)
Adherence improved but not 
QoL
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TA B L E  2  Evidence synthesis of randomised controlled trials using behaviour change to improve diet in the last 5 years
Author Year Intervention groups Participants Duration Outcomes Behaviour change components Dietary change Results
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2020; Piernas et al., 2019)
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wheel) (Group 2 and 3)
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purchasing between groups
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compared to control
Duś- Żuchowska et al. (Duś- Żuchowska 
et al., 2018)
2018 1. Mediterranean Diet
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Ml – improved ALT and liver 
stiffness
ML and MD – weight loss
Kazemi et al. (Kazemi et al., 2018) 2018 1. Pulse- based diet





Two meals (i.e., lunch and dinner) were 
supplied daily for participants in the 
pulse- based diet group
Differences in fibre and micronutrient 
intakes between groups (24- h recalls)
Pulse- based diet decreased 
total insulin AUC, levels of 
LDL- C, TG, TC/HDL- C ratio, 
diastolic blood pressure, 
and increased HDL- C 
compared to control diet
Krishnan et al. (Krishnan et al., 2018) 2018 1. Typical American Diet (TAD)
2. Dietary Guidelines America diet (DGA)
Overweight to obese women, 
less than 150 min/week 
physical activity
≥1 cardiometabolic risk factor
n = 52
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39 ± 31 (13.9% ± 0.1%) instances of 
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50% of the daily intake during 5 
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Intakes of fibre, EPA, and DHA were 
considerably higher during the 
intervention period (3- d diet record)
No significant differences 
between groups
Jayawardena et al. (Jayawardena et al., 
2017)
2017 1. Control






Personalised advice Not reported Weight reduction relative to 
control. No change in BP 
or lipids
Koutoukidis et al. (Koutoukidis et al., 2017; 
Koutoukidis et al., 2019) [DEUS]
2017 1. Control




8 weeks Adherence to AHEI 2010 
score
Quality of Life (QoL)
Group sessions 77% adhered to intervention (AHEI results 
not reported)
Adherence improved but not 
QoL
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behavioural interventions at scale, with a focus on fi-
delity, adherence, effectiveness and efficacy. He sum-
marised that a whole systems approach was needed 
for complex behavioural interventions, which compli-
cated the evaluation and interpretation of the trial re-
sult, but would be more likely to facilitate maintenance 
of changed behaviour over time and improve health 
outcomes.
Finally, Paul Aveyard from the University of Oxford 
spoke about the trial design options. This started with 
a reminder of the MRC Framework for complex in-
tervention development and reinforcing the value of 
defining the behavioural theory underpinning the pu-
tative intervention (Craig et al., 2008). Given this is a 
trial aiming for a long- term health outcome, it is vital to 
ensure the intervention had the best chance of achiev-
ing sustained dietary change. The presentation then 
passed on to novel trial designs that may be employed 
in early- stage development work, such as the multi-
phase optimisation strategy trial design, that can help 
determine the effect of particular components of an in-
tervention, and the value of adaptive designs in finding 
ways to maximise the benefit of a behavioural support 
programme (Wyrick et al., 2014). Finally, he presented 
an explanatory- pragmatic trial continuum to fuel debate 
about which end of the spectrum we would want to sit-
uate this work.
Breakout rooms and general discussion
Four breakout rooms then discussed the PICO ele-
ments on the study design in depth, and fed back to the 
entire group their main points. See Table 1 for a sum-
mary of the discussed PICO elements.
When the breakout rooms fed back to the final discus-
sion, a consensus emerged that there was a need and a 
will to proceed with the NuLifE programme. It was noted 
that it was especially important to consider how such 
a trial might help address health inequalities, perhaps 
by recruiting specifically in areas of high deprivation. 
The other main area of discussion was whether NuLifE 
would be an efficacy trial, focussed on answering the 
question of the strength of the impact of a healthy diet 
on the risk of disease outcomes; or an effectiveness 
trial, demonstrating the impact of a pragmatic dietary 
intervention on a representative sample of the UK.
Subsequently between workshops, comments were 
sought online on three possible study designs.
1. An individual- level efficacy (explanatory) RCT aiming 
to change dietary behaviours and reduce incident 
disease in UK adults.
2. An individual- level effectiveness (pragmatic) RCT 
aiming to change dietary behaviours and reduce in-
cident disease in UK adults.
3. A population- level cluster (area/town/city) RCT aim-
ing to influence structural (social, cultural, economic, 
geographical and other environmental) determinants 
of eating behaviour, improving eating behaviour and 
nutrient status in UK adults, and reducing the risk of 
incident disease in UK adults.
NULIFE WORKSHOP 2
At the start of the second NuLifE workshop, AMM 
began with a summary of the first workshop and the 
online working documents. The online working docu-
ment of potential study designs between sessions had 
reached an agreement that there was insufficient justi-
fication to proceed with an explanatory RCT (#1 above) 
for the following reasons:
• To run a true whole- diet efficacy RCT with long- term 
outcomes, we would need to be very confident of the 
ability to implement an intervention with high fidelity, 
and with a compliant (pre- screened, selected and 
monitored) population group, to have the power to 
detect outcomes. It would be practically very chal-
lenging to get the compliance needed for the level of 
certainty required.
• Furthermore, such an approach would likely divert 
attention from populations where there is greatest 
need (i.e. participants in communities with high levels 
of deprivation).
Author Year Intervention groups Participants Duration Outcomes Behaviour change components Dietary change Results
Ananad et al. (Anand et al., 2016) 2016 1. Control




1 year Myocardial infarction risk 
score
Stages of change motivational message 
and health tips every 2 weeks
Not reported No change between groups





1 year 10- year cardiovascular 
risk
Counselling session (1 × 25 min) and 
individualised meal plans
Not reported No change between group
Abbreviations: AHEI, alternative healthy eating index; ALP, Alkaline phosphatase; ALT, alanine aminotransferase; AUC, area under the curve; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid; FFQ, food frequency questionnaire; HDL- C, high- density lipoprotein cholesterol; HOMA- IR, 
Homeostatic Model Assessment for Insulin Resistance; LDL- C, low- density lipoprotein- cholesterol; MEDAS, Mediterranean Diet Adherence Screener; TC, 
total cholesterol; TG, triglyceride.
TA B L E  2  (Continued)
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• An efficacy trial would need to be followed by effec-
tiveness trials if the results are going to inform public 
health policy.
• As a result, the higher priority and best use of re-
sources would be to conduct a pragmatic trial in de-
prived communities where the poorest adherence to 
dietary guidelines is evident. Such a trial is likely to 
be more informative and impactful than a similarly 
sized trial in the general population.
Although there was a strong rationale for a cluster 
intervention approach (#3 above), which focussed on 
contextual modulators of eating behaviour, the devel-
opment of such an intervention appeared currently un-
realistic as it would be reliant on enactment of several 
fiscal, food and health- related policy changes; and a 
much greater understanding of the relative structural 
determinants of food purchasing and eating behaviour 
than is currently available.
The consensus was clear, that NuLifE would pro-
ceed with planning an effectiveness (pragmatic) trial fo-
cussed on examining the impact of an eating behaviour 
intervention on incident disease in communities with a 
high score on the IMD.
Such an approach is aligned with the public health 
policy need as reflected in:
1. the UK Government Ageing Society Grand 
Challenge mission (BEIS, 2019);
2. the Public Health England's Strategy 2020– 2025, 
around healthy inequalities and healthy ageing (PHE, 
2019);
3. current health and behaviour inequalities, aggravated 
and highlighted by the COVID- 19 pandemic and its 
impact on COVID- 19 prognosis (Bambra et al., 2020);
4. reports such as Health equity in England: The 
Marmot review 10 years on (Marmot, 2020).
Prior to the second meeting, the working group 
agreed that it was clear we were lacking a consensus 
on the intervention approach for NuLifE. It was decided 
that we needed an evidence synthesis of eating be-
haviour interventions to help inform the discussion.
Evidence synthesis of eating behaviour 
interventions
Changing eating behaviour is hugely challenging, with 
numerous social, cultural, economic, environment 
and geographical variables influencing food purchase 
and consumption. Prior to workshop 2, a systematic 
search of the empirical evidence was conducted by AJ 
(University of East Anglia) to inform the discussion and 
to establish the evidence for the impact of various in-
terventions on attainment and maintenance of eating 
behaviour change. Search terms looked for any RCT 
on diet and disease in adults that did not involve sup-
plements, which was published since 2015; the search 
was extended to also look for any RCTs on diet con-
ducted in the UK since 2010. Results were excluded 
if the trials did not involve behavioural change or were 
lacking diet- only treatment arms (see Appendix B for 
more details). The following intervention approaches 
were focussed on and summarised, along with their 
results:
1. food/meal provision
2. cash incentives, food vouchers, supermarket delivery
3. digital intervention
4. personalisation
5. education and cookery skills
6. Behaviour Change Technique (BCT)- based
7. group sessions and peer support
8. community- based intervention.
Results from trials run in the last 5 years are sum-
marised in Table 2 (further results are in Appendix B). 
Many trials were conducted in healthy individuals who 
were not selected on the basis of the quality of their 
diet and hence many had adequate diets at baseline. 
A range of dietary components were targeted and, in 
many cases, an exact definition of dietary improvement 
was not detailed. It was therefore difficult to conclude if 
the studies that reported no effect on health outcomes 
were due to poor adherence or a true lack of effect. With 
such heterogeneity in the results, it was not possible 
to reach a consensus on which whole diet intervention 
Author Year Intervention groups Participants Duration Outcomes Behaviour change components Dietary change Results
Ananad et al. (Anand et al., 2016) 2016 1. Control




1 year Myocardial infarction risk 
score
Stages of change motivational message 
and health tips every 2 weeks
Not reported No change between groups





1 year 10- year cardiovascular 
risk
Counselling session (1 × 25 min) and 
individualised meal plans
Not reported No change between group
Abbreviations: AHEI, alternative healthy eating index; ALP, Alkaline phosphatase; ALT, alanine aminotransferase; AUC, area under the curve; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid; FFQ, food frequency questionnaire; HDL- C, high- density lipoprotein cholesterol; HOMA- IR, 
Homeostatic Model Assessment for Insulin Resistance; LDL- C, low- density lipoprotein- cholesterol; MEDAS, Mediterranean Diet Adherence Screener; TC, 
total cholesterol; TG, triglyceride.
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approaches would be most likely to provide individuals, 
families and communities with the capability, opportu-
nity and motivation to enact and maintain eating be-
haviour change. It was also clear that research aimed 
at enacting dietary behaviour change in deprived com-
munities was particularly scarce.
Presentations and breakout rooms 
focussed on intervention
The presentations and breakout room discussions 
for the second workshop all focussed around defin-
ing an effective eating behaviour intervention. First, 
spokespeople from previous whole- diet interventions 
(JM from Food4Me, AJ from NuAge, Wendy Hall from 
CRESSIDA, AMM from MedEx) summarised key in-
sights from their studies (details of these studies are 
summarised in Appendix B).
Breakout rooms chaired by members of the working 
group (NS, SJ, JC, JM) then discussed the intervention 
components as a first priority, and the study popula-
tion or key endpoints as a second priority. Feedback 
and general discussion amongst the entire group re-
vealed that there was a general enthusiasm for target-
ing groups with high IMD scores of deprivation as a 
unique component of NuLife. However, there was also 
a consensus that the NuLifE trial would need to be con-
ducted in stages in order to achieve its ultimate goal, 
requiring a strong community co- creation, pilot and fea-
sibility phase in order to proceed with confidence with 
an eating behaviour intervention strategy which is fit for 
purpose.
STAGE 1: TAILORING COMPLEX 
DIETARY INTERVENTIONS TO 
COMMUNITIES WITH A HIGH INDEX 
OF MULTIPLE DEPRIVATION
Stage 1 of the NuLifE programme will be a community- 
based (high IMD communities), Patient and Public 
Involvement informed, project to co- design, develop 
and test the NuLifE intervention approaches to increase 
the agency of residents to enact eating behaviour 
within the Eatwell guidelines. The intervention will be 
developed based on the MRC Developing and evaluat-
ing complex intervention guidelines (Craig et al., 2008). 
In addition, the intervention will be co- developed and 
co- produced with organisations such as the Integrated 
Care Systems, Community Foundations, FoodBanks/
Trussell Trust, community- embedded food retailers (e.g. 
Co- op/ALDI) and build on existing community assets. 
Both personalised (to the individual's baseline health 
and eating behaviour status) and contextual interven-
tion components will be considered, with the ultimate 
aim to provide individual and communities with the ca-
pability, opportunity and motivation to enact healthier 
eating behaviours which aim to increase HALE and re-
duce chronic disease onset (Michie et al., 2011).
STAGE 2: ONE- YEAR 
EFFECTIVENESS TRIAL ON 
INTERIM END POINT OF 
BLOOD PRESSURE
The NuLifE consortium then agreed that Stage 2 of the 
NuLifE programme would be an interim step to test the 
effectiveness of a one- year intervention of the NuLifE 
approach with blood pressure as the primary endpoint. 
Blood pressure is a robust target due to its strong prog-
nostic value for future cardiovascular diseases, and it 
is influenced by a wide array of foods and macro- and 
micro- nutrients and non- nutrient bioactives (Jennings 
et al., 2019; Ndanuko et al., 2016).
STAGE 3: LARGE-  SCALE 
EFFECTIVENESS PRIMARY 
PREVENTION RCT
Finally, Stage 3 would be to run a full effectiveness pri-
mary prevention RCT of the NuLifE intervention to as-
sess the effect on incident disease.
CONCLUSION
We thank the MRC for funding this workshop, which 
provided the impetus for over 40 experts from a range 
of disciplines to come together over 6 months. Through 
two workshops, along with online discussions and a 
systematic evidence synthesis, the first UK nutrition, 
primary prevention, effectiveness trial took shape. The 
workshops delivered a three- stage plan with the ulti-
mate ambitious aim of establishing a multi- disciplinary 
and multi- agency approach, alongside effective eat-
ing behaviour change strategies, to address the grow-
ing inequalities in the UK and contribute to a reduced 
risk of prevalent diet- related chronic disease and in-
creased HALE. Such an approach directly addresses 
the Government's ‘Ageing Society’ Grand Challenge to 
‘ensure that people can enjoy at least 5 extra healthy, 
independent years of life by 2035, while narrowing the 
gap between the experience of the richest and poorest’ 
(BEIS, 2019).
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APPENDIX A
WORKSHOP ATTENDEES
Surnames First Name Organisation Expertise/Research Interests
Ángel Martínez González Miguel Universidad de Navarra Mediterranean diet and health, PREDIMED
Armitage Jane University of Oxford large- scale clinical trials in cardiovascualr disease
Aveyard Paul University of Oxford behavioural medicine, weight loss, disease 
prevention or treatment
Brayne Carol University of Cambridge neuroscience, epidemiology, aging
Cade Janet University of Leeds nutritional epidemiology, diet assessment methods
Calder Philip University of Southampton nutritional modulation of immunity, inflammation 
and disease risk
Carter Jennifer University of Oxford nutrition, adiposity, epidemiology and statistics
Clarke Philip University of Oxford health economics, health inequalities, diabetes
Curtis Peter UEA diet, fruit and vegetables, flavonoids, RCT, 
cardiovascular
Daley Amanda Loughborough University lifestyle interventions within health care and health
Dobson Paul UEA business strategy, public policy, food supply and 
retailing
Dye Lousie University of Leeds nutrition and cognitive function across the lifespan
Fairweather- Tait Susan UEA micronutrients and health
Gill Jason Glasgow University metabolic responses to exercise and diet
Godfrey Keith University of Southampton nutritional epidemiology and human development
Gray Cindy Glasgow University health behaviour change
Gray Alastair University of Oxford health economics, large randomised trials
Griffin Bruce University of Surrey nutritional biochemistry, lipid metabolism, health
Haczewski Tom The User Story SME, Norwich evidence- based digital product business
Hall Wendy KCL nutritionist, clinical trials, public health policy
Haynes Richard University of Oxford large clinical trials in cardiovascular and metabolic 
disease
Hornberger Michael UEA applied dementia research
Hunt Kate University of Stirling behaviour change and health inequalities
Jackson Kim University of Reading dietary fats, genotype, lipoprotein metabolism
Jebb Susan University of Oxford trials, weight loss, diet and obesity- related 
diseases
Jennings Amy UEA diet, ageing, microbial and metabolite profiles, 
health
Lietz Georg University of Oxford micronutrients, nutrigenomics, inter- individual 
variation
Lovegrove Julie University of Reading nutigenetics, nutrigenomics, cardiovascular 
disease
Mathers John Newcastle University aging, nutrition, molecular biology, epidemiology
McNulty Helena University of Ulster nutrition- related health issues, food and health 
policy
Mela David Consultant (Food Industry) nutritional science and metabolic health
Milne Eugene Newcastle Public Health Director of Public Health, inequalties
Minihane Anne Marie UEA diet, nutrigenetics and cardio- metabolic and 
cognitive health
Naughton Felix UEA phone interventions to support health behaviour 
change
Petrou Stavros University of Oxford health economics, trial- based economic 
evaluations
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Surnames First Name Organisation Expertise/Research Interests
Rogers Peter University of Bristol nutrition, behaviour, obesity and psychological 
health
Sattar Naveed Glasgow University epidemiology of diabetes, obesity and heart 
disease
Smith Louise Norfolk Public Health Director of Public Health, health and wellbeing
Sniehotta Falko Newcastle University trials, behavioural change, health
Whitty Jenny UEA applied health economist
Wildman John Newcastle University health economics, health inequalities
APPENDIX B
SYSTEMATIC SEARCH OF THE EMPIRICAL EVIDENCE ON EATING BEHAVIOUR CHANGE 
INTERVENTIONS
What is the evidence for the impact of various interventions on attainment and maintenance of eating behaviour 
change?
Randomised controlled trials using behaviour change to improve diet (focused on whole diet).
PUBMED SEARCH [1]
randomized controlled trial AND diet AND disease AND ((double blind OR single blind)) AND adult NOT supplement
Filter 2015– 2021
[n = 391]
Excluded studies reporting single dietary components or supplements, multi domain interventions, without clearly 
defined behaviour change elements or lacking diet only treatment arms.
Results reported in main text.
PUBMED SEARCH [2]
Randomized controlled trial AND diet AND disease AND ((double blind OR single blind)) AND adult NOT supple-
ment AND ((United Kingdom) OR UK).
Filter 2010– 2021
[n = 94]
Excluded studies reporting single dietary components or supplements, multi domain interventions, without clearly 
defined behaviour change elements, lacking diet only treatment arms or not conducted in the UK.
Results reported in Table B1.
ADDITIONAL STUDIES [3]
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